studies of nicotinic acetylcholine receptors (nAChRs) in the human brain [1] . Such studies have the potential to elucidate the role of nAChRs in normal brain function as well as in pathological states that are thought to involve these receptors (e.g., Alzheimer's disease,
Parkinson's disease, nicotine dependence) [2] [3] [4] [5] [6] [7] [8] . In vivo imaging of nAChRs also may be helpful in evaluating and establishing dosage regimens for medications targeting or interacting with nAChRs.
[ 11 C]Nicotine was the first PET radioligand used for studying brain nAChRs in vivo [9] . It has substantial drawbacks that include a high degree of non-specific binding, strong dependency of cerebral accumulation on cerebral blood flow, and rapid dissociation from the receptor-ligand complex [10] [11] [12] . Other 11 C-labeled radioligands, such as 3-[(1- [16, 17] , however, spatial resolution and sensitivity of SPECT are generally lower than those of PET. 2-[ 18 F]FA lacks some of the disadvantages of previous nAChR probes [1, 18] , and exhibits high accumulation in the human thalamus [1] , consistent with the known brain regional distribution of nAChRs [19] . Parallel work has been done using another compound of this series, 6-[ 18 F]FA [20] . 4 We undertook this study to determine the maximal dose of 2-[ 18 F]FA that can be safely administered intravenously in human subjects, in order to obtain the highest quality PET images without exceeding accepted radiation dosimetry guidelines. Previous estimates of radiation absorbed dose for 2-[ 18 F]FA were based on the measured activity in only several critical organs and conservative assumptions regarding activity that was not directly measured [1, 21] . We performed radiation dosimetry studies on two healthy human volunteers to obtain time-activity data for all target organs, and compared the resulting radiation absorbed dose estimates with previously reported values.
Materials and methods

Subjects
Two healthy men (ages: 23 and 39 years; weights: 68 kg for both subjects) with IQ Institutional Review Board approved the imaging research protocol and informed consent was obtained from the research subjects before imaging. The radioligand was administered to the human volunteers under VA GLAHS RDRC approval. 5 
Whole body PET imaging
The radiopharmaceutical 2-[ 18 F]FA was prepared as described previously [18] . At predetermined intervals, starting immediately after the 2-[ 18 F]FA administration to 1 h post-injection, the participants were asked whether they felt effects of the injected radioligand. Heart rate, blood pressure, respiratory rate, and ECG parameters were monitored at predetermined intervals throughout the 3-h scanning period. 6 
Radiation absorbed dose estimates
Reconstructed PET images were used to identify and evaluate the activity in each source organ listed in Table 1 . Regions of interest (ROI) were manually drawn within the boundaries of organs in adjacent transaxial slices at each time point. Organs demonstrating low activity on the transverse projection were first identified on coronal or sagittal whole body images, which provide greater anatomic detail, and then localized on transverse planes using triangulation to delineate their boundaries. For each time point of a dynamic scan, data from each ROI (counts/pixel) were corrected for time of acquisition and tomograph efficiency using the phantom data. These results were converted to units of MBq/ml. The specific measurement time assigned to each organ was the estimated midpoint of the time that the organ was in the scanner field of view during each of the sequential whole-body scans. Mean activity per unit volume was calculated from all ROIs for each organ, assuming a uniform distribution of activity within the organ. This value was divided by the organ tissue density, multiplied by the standard reference organ weight [25] , and divided by the administered activity in order to estimate the fraction of administered activity in the given organ at a given time point. The administered activity was first adjusted by multiplying it by the ratio of the actual patient weight and the standard patient weight of 70 kg. We assumed the lung tissue density to be 0.33 g/ml and the tissue density of other organs to be 1.0 g/ml [26] .
For all organs except the bladder, residence times (in hours) were determined using trapezoidal integration of the decay-corrected time-activity curve from zero time to the time of the last PET scan. Thus, four time points were used to construct each time-activity curve. Residence time for a source organ was defined as the area under the decay-7 corrected time-activity curve, divided by the amount of activity administered. Beyond the last time point, we assumed physical decay of the 18 F label without biological clearance.
The residence time of the urinary bladder content was calculated by applying the dynamic bladder model according to Cloutier [27] , which is included in the MIRDOSE 3.0 program. Internal Radiation Dose (MIRD) system [28] . To perform the final radiation-absorbed-dose calculations, the residence times were transferred to the MIRDOSE program (Version 3.0, ORISE, Oak Ridge, TN) [29] , which yielded the single-organ radiation absorbed doses as well as the effective dose equivalent.
Results
On early PET whole body images, 10 min after injection of 2-[ 18 F]FA, intense activity was seen in the liver, kidneys, and intestines; and low activity was observed in the lungs, brain, and heart wall. On later images, 2-3 h after injection of the radioligand, activity was markedly retained within the urinary bladder, liver, kidneys, bone marrow, brain, and the spleen. A representative coronal whole-body PET image, obtained at 118 min after 2-[ 18 F]FA administration, is shown in Figure 1 .
Place Figure 1 approximately here.
The residence times for each measured source organ, except the urinary bladder, are shown in Place Tables 1 and 2 approximately here.
Discussion
This study was conducted to estimate the radiation absorbed dose resulting from the According to the Code of Federal Regulations (CFR), in research subjects, the single dose limit to blood-forming organs, the gonads, and the whole body is 3 rem, and the annual and total dose commitment limit is 5 rem [30] . Furthermore, the single-dose limit for urinary bladder wall is 5 rem, and the annual and total dose-commitment limit is 15 rem. data. The radioactivity distribution was assumed to be homogeneous throughout each organ. During dynamic PET imaging, the radioligand clearance occurs by both biological elimination and physical decay, however, the clearance was assumed to have only physical decay component after the final imaging time point. This conservative assumption should result in an overestimation of the calculated radiation absorbed doses. Furthermore, residence times were determined using trapezoidal integration of time-activity data for all organs except the bladder. Finally, this study did not evaluate the radiation absorbed dose to the ovaries and uterus, since only male research subjects participated in our study.
Nonetheless, Kimes et al., who included at least one female subject in their study did not report remarkable radioactivity in the uterus or the ovaries [1] .
Our report extends previous work to estimate radiation absorbed dose resulting from administration of 2-[ 18 F]FA [1, 21] . In one of the previous reports, residence time for the urinary bladder was determined from excreted radioactivity in 6 subjects, and residence times for seven organs were determined from data obtained in 2 or 3 subjects with three whole body scans for each [1] . That report provided the absorbed dose equivalent for the urinary bladder wall, kidneys and liver, and a combined value for all other organs. In this study, we report radiation-dosimetry estimates, which were obtained using activity data for 20 source organs (Table 1) . Our estimated radiation absorbed doses for the testes, thyroid gland, lungs, and heart wall exceed those reported in one of the two previous reports on this topic [21] . However, the prior study, which included 3 subjects, did not evaluate the residence times of these organs and did not provide an account of the contribution of the actual activity of these organs to their radiation absorbed doses. If not considered, these factors would result in an underestimation of radiation absorbed doses. 
